Last week Cytel joined forces with Sanofi/Genzyme to devote a full day of workshops and talks related to modern methods in early phase oncology. Patrick Mitchell, an Associate Director of Statistical Sciences at Astra Zeneca, gave this talk on Bayesian go/no-go decision-making in an early phase oncology event study.
Astra Zeneca recently invited Cytel to take part in a collaborative initiative to develop software for go/no-go decision-making. Pat demonstrates the uses of this proprietary software in early phase oncology.
James Matcham, the Head of Early Clinical Development Biometrics at Astra Zeneca will also be giving a talk on go/no-go decision-making at the European Statistical Forum later this month. Click below to see the abstract of his talk and to register for ESF 2015.